Dr. Falk exercises option for Lipid's UC product

Dr. Falk Pharma GmbH (Freiburg, Germany) exercised an option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics GmbH (Heidelberg, Germany). Lipid Therapeutics will receive an undisclosed upfront payment and will be eligible for milestones and royalties. According to Dr. Falk, the decision to exercise the option was based on the "positive outcome" of a Phase IIb trial. Last June, Lipid said LT-02 met the trial's primary endpoint of reducing Simple Clinical Colitis Activity Index (SCCAI) scores from baseline to week 12 vs. placebo (51% vs. 33%, p<0.05). ...